SWP
PVLA

Stratos Wealth Partners’s Palvella Therapeutics PVLA Stock Holding History

Stratos Wealth Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-156
Closed -$65K – 1308
2021
Q3 		$65K Hold
156
– – ﹤0.01% 1159
2021
Q2 		$48K Buy
+156
New +$34.2K ﹤0.01% 1172

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stratos Wealth Partners's PVLA Position: Q4 2021 in Review

Stratos Wealth Partners sold out of Palvella Therapeutics (PVLA) in Q4 2021, closing a stake of 156 shares — an estimated $65K sold.

Stratos Wealth Partners first reported a position in PVLA in Q2 2021 and held it in 2 quarters. The position peaked at $65K in Q3 2021. 81 funds tracked by Wall St. Rank hold PVLA as of Q4 2021.

  • Stratos Wealth Partners reported no remaining Palvella Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Stratos Wealth Partners sold 156 Palvella Therapeutics shares in Q4 2021, an estimated $65K.
  • Stratos Wealth Partners first reported a position in Palvella Therapeutics in Q2 2021 and held it in 2 quarters.
  • Stratos Wealth Partners's Palvella Therapeutics position peaked at $65K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2021.

Based on Stratos Wealth Partners's 13F filing for Q4 2021, filed 14 Jan 2022.